Clinical Trials Logo
  1. Home
  2. Psychotic Disorders
  3. NCT02873884
  4. Details
NCT02873884 Clinical Trial

Impact of Case-management on Therapeutic Alliance With First Episode Psychosis Patients (CAMAT)

Psychotic Disorders Clinical Trial

— CAMAT  

Official title:
Impact of Case-management on Therapeutic Alliance With First Episode Psychosis Patients (CAMAT)

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02873884
Other study ID # CAMAT
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 2016
Est. completion date November 2019

Study information
Verified date April 2019
Source University Hospital, Caen
Contact Laurent Lecardeur, PhD
Email lecardeur@cyceron.fr
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The first aim of this study is to test the effect of the case management on the evolution of therapeutic alliance in patients with first episode psychosis in comparison with traditional nursing. The second aim is to test the effect of case management on nurses' well-being in comparison with traditional nursing. The third objective aims to show if therapeutic alliance is associated with insight in patients and with clinical and demographic data.

Recruitment information / eligibility
Status Recruiting
Enrollment 30
Est. completion date November 2019
Est. primary completion date November 2019
Accepts healthy volunteers No
Gender All
Age group 16 Years to 30 Years
Eligibility Inclusion Criteria:

- Age between 16 and 30 years

- First episode psychosis diagnosis according to DSM-5 criteria

Exclusion Criteria:

- Lees of 16 years or more than 30 years

- Not fulfilling DSM-5 criteria for first episode psychosis

- Any treatment with the psychologist or the psychiatrist of the team

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• Case-management

Locations
Country Name City State
France CHU de Caen Caen

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Caen

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Work alliance inventory 6 months
Secondary Birchwood insight scale 6 months
Secondary Scale to assess Unawareness of Mental Disorder 6 months
Secondary Well-being at work scale 6 months
See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Terminated NCT03230097 - This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year Phase 2
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Active, not recruiting NCT05726617 - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders N/A
Not yet recruiting NCT03807388 - ReMindCare App for Patients From First Episode of Psychosis Unit. N/A
Recruiting NCT02874573 - Tocilizumab in Schizophrenia Phase 1
Completed NCT02906553 - The Role of Nitric Oxide in Cognition in Schizophrenia N/A
Terminated NCT02584114 - Brain Effects of Memory Training in Early Psychosis N/A
Terminated NCT02841956 - Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement N/A
Withdrawn NCT02213887 - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications Phase 4
Completed NCT01981356 - Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis Phase 0
Recruiting NCT02009969 - Serial Comparisons of Abdominal and Neurological MRI Scans N/A
Recruiting NCT02848469 - Irish Omega-3 Study Phase 2
Completed NCT02648321 - Motivational Intervention for Physical Activity in Psychosis N/A
Enrolling by invitation NCT00762866 - Psychiatric Genotype/Phenotype Project Repository
Completed NCT00484302 - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis N/A
Completed NCT00130923 - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Phase 4
Completed NCT00844922 - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842) Phase 2
Completed NCT00455234 - Rapid Tranquillization Trial: TREC-India II Phase 3
Completed NCT00226278 - Safety Study of ORG 34517 for Major Depression With Psychotic Features Phase 2